Clinical Trial

JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)

Name: JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs) — clinical trial record (NCT06887985)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with Refractory Autoimmune Diseases (ADs). It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of Refractory Autoimmune Diseases (ADs).

Trial Details

NCT Number	NCT06887985
Lead Sponsor	He Huang
Conditions	Autoimmune Diseases
Enrollment	45 participants
Start Date	2025-03-31
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-03-21